NASDAQ:HELP

Cybin Q3 2026 Earnings Results & Report

Cybin logo
$6.11 -0.67 (-9.88%)
Closing price 04:00 PM Eastern
Extended Trading
$6.16 +0.05 (+0.90%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cybin missed analyst earnings expectations in its Q3 2026 results, released February 13, 2026. The company reported EPS of -$0.72 versus the -$0.53 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
12:30 PM ET

Cybin EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.19
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Cybin Q3 2026 Earnings FAQ

Cybin (NASDAQ:HELP) reported earnings of -$0.72 per share for Q3 2026, missing the consensus estimate of -$0.53. The report was announced on Friday, February 13, 2026.

Cybin Earnings Headlines

Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP), which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders.

The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder. These compounds remain investigational and are not approved medicines.

Founded in 2019, the company has conducted clinical development activities in multiple countries. Doug Drysdale has served as its chief executive officer.

View Cybin Profile